Obermatt
See Similar Stocks →

Rocket Pharmaceuticals

NMQ:RCKT · US77313F1066
BiotechnologySmall

360° View

31
Price/Sales52
Price/Earnings54
Price/Book56
Dividend Yield1
Revenue Growth—
Profit Growth50
Capital Growth88
TSR 52w14
Leverage52
Liquidity27
Refinancing15
Combined75
Analyst Opinions9
Pro Holdings71
Opinion Changes19
Market Pulse31

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees217
Websiterocketpharma.com
ISINUS77313F1066
Last UpdateApr 2, 2026
Index & Theme
CardiovascularStem Cell TherapyGeneticsHematologyGenetic DisorderBiotechnologyHealth CarePharmaceutical

Description

Rocket Pharmaceuticals, Inc. operates as a fully integrated, late-stage biotechnology company. The company focuses on the development, manufacturing, and potential commercialization of genetic therapies for rare, and often fatal diseases with high u…

Analysis

Rocket Pharmaceuticals's 360° View rank of 31 places it below its peer average — better than 31% of its true peers.

It's growing solidly (73) and looks cheap versus peers (78). On safety it is highly leveraged (10), and the market shows skeptical sentiment (13). Taken together, its Combined rank of 75 reads as above its peer average.

360° rank · history

1007550250
31
2026

All-time high

33

Mar 2026

All-time low

31

Jun 2026

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
—
—
—
Price/Earnings
54
—
—
—
Price/Book
56
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
78
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rocket Pharmaceuticals with its peers
Solid Biosciences
NSQ:SLDB
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Lexeo Therapeutics
NMQ:LXEO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cytokinetics
NSQ:CYTK
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →